News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
CAMP4 Therapeutics Receives Australian Clearance to Begin First-in-Human Trial of CMP-002 for SYNGAP1-Related Disorder
Tuesday, July 28, 2026CAMP Therapeutics has received regulatory clearance from Australias Therapeutic Goods Administration TGA and approval from a local Human Research Ethics Committee HREC to begin its Phase clinical trial of CMP an investigational treatment for SYNGAPr...
IDEAYA begins Phase 1/2 expansion study of IDE892 in MTAP-deleted pancreatic and lung cancers
Monday, July 27, 2026IDEAYA Biosciences has initiated Part of the Phase clinical trial evaluating IDE its investigational methylthioadenosine MTAcooperative PRMT inhibitor as a monotherapy for patients with MTAP
Ipsen Reports Phase III BOLD Trial Results in Biliary Atresia
Friday, July 24, 2026Ipsen has announced that its Phase III BOLD trial evaluating Bylvay odevixibat in patients with biliary atresia BA who had previously undergone Kasai hepatoportoenterostomy HPE did not meet its primary endpoint of improving native liver survival comp...
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for IKT-001 in PAH
Friday, July 24, 2026Inhibikase Therapeutics has received US Food and Drug Administration FDA Orphan Drug Designation ODD for IKT its lead product candidate for the treatment of pulmonary arterial hypertension PAH
Revolution Medicines' NDA for Daraxonrasib Accepted for FDA Review in Metastatic Pancreatic Cancer
Thursday, July 23, 2026Revolution Medicines has announced that the US Food and Drug Administration FDA has accepted for review its New Drug Application NDA for daraxonrasib an investigational oral RASON multiselective inhibitor
Healx Doses First Patient in Phase 1/2 Trial of HLX-4310 for Relapsed and Refractory Sarcomas
Thursday, July 23, 2026Healx has announced that the first patient has been dosed in a Phase clinical trial evaluating HLX an investigational oral combination therapy for adolescents and adults with relapsed or refractory sarcoma with a particular focus on osteosarcoma
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
Tuesday, July 21, 2026Telix Pharmaceuticals has dosed the first patient in the Phase LUTEON trial of TLXTx lutetium girentuximab tetraxetan marking the first radiopharmaceutical therapy to enter Phase
Innate Pharma Completes Phase 1 Dose Escalation Enrolment for IPH4502 ADC Study
Tuesday, July 21, 2026Innate Pharma has completed patient enrolment in the doseescalation stage of its Phase IPH clinical trial which is evaluating IPH the companys proprietary Nectintargeting exatecan antibodydrug conjugate ADC in patients with advanced solid tumours
Immunome Doses First Patient in Phase 1 Trial of IM-3050 for Advanced Solid Tumours
Tuesday, July 21, 2026Immunome has dosed the first patient in a Phase firstinhuman clinical trial evaluating IM an investigational fibroblast activation protein FAPtargeted radioligand therapy in patients with FAPexpressing advanced solid tumours
Dyne Therapeutics’ BLA for Z-Rostudirsen Accepted by FDA for Review in Exon 51 Duchenne Muscular Dystrophy
Monday, July 20, 2026Dyne Therapeutics has announced that the US Food and Drug Administration FDA has accepted its Biologics License Application BLA for zeleciment rostudirsen zrostudirsen also known as DYNE
